04:21 AM EDT, 10/13/2026 (MT Newswires) -- Solvonis Therapeutics (SVNS.L) signed a memorandum of understanding with Portugal's addiction institute ICAD and clinical partner Panegreen to assess adding Portuguese sites to MORE-KARE, the UK Phase 3 trial of SVN-001 for severe alcohol use disorder. The late-stage clinical biopharmaceutical company said Tuesday the initial six-month, non-binding MoU will explore how Portuguese services and clinical facilities could support the trial and the potential inclusion of Portuguese patients to strengthen the evidence base for future marketing applications.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.